SLU-PP-332 1000mcg

SLU-PP-332 is a small-molecule research compound that acts as a pan-agonist at the three estrogen-related receptor (ERR) family members — ERRα, ERRβ, and ERRγ. These nuclear receptors are not bound by estrogen itself (despite the name), and have remained orphan receptors for most of their characterization history; the discovery of useful synthetic agonists has opened ERR pharmacology to the broader research community. SLU-PP-332 was developed by researchers at Saint Louis University and the Burnett School of Biomedical Sciences as part of a structure-guided design program. We supply SLU-PP-332 as a research-grade compound for laboratory study of ERR-dependent gene expression. This guide explains what it is, the research context, and how each batch is verified.

SLU-PP-332 is a small organic molecule — not a peptide. It is supplied as a solid for laboratory reconstitution in a research-appropriate solvent. The compound is dosed at the microgram scale in animal models, which is reflected in our 1000mcg vial format; the relatively low per-dose mass is typical for small-molecule nuclear-receptor agonists with high target affinity. Exact molecular weight, formula, and structural notation are documented on each batch's Certificate of Analysis, since the compound's structural detail is part of the active research record.

SLU-PP-332 is sold strictly for laboratory and research use. It is not approved by the FDA or any other regulatory body for human or veterinary use, and nothing in this guide constitutes guidance for human administration.

Published research on SLU-PP-332 centers on its activity as a pan-agonist of the ERR family. The three ERR isoforms have overlapping but tissue-specific expression patterns: ERRα is widely expressed with particular prominence in metabolically active tissues, ERRβ has more restricted expression, and ERRγ is enriched in muscle, heart, and brown adipose tissue. Animal-model work has examined SLU-PP-332's effects on ERR-driven gene expression programs that regulate mitochondrial biogenesis, oxidative metabolism, and skeletal-muscle adaptation — pathway elements that overlap with what is sometimes described as an 'exercise-mimetic' research profile. Researchers should evaluate the original SLU-team publications and the broader ERR-pharmacology literature directly.

Because SLU-PP-332 is a small molecule rather than a peptide, the analytical approach is the same in principle as for our small-molecule peptide-adjacent compounds (5-Amino-1MQ, L-Carnitine), with methodology appropriate to organic synthesis. Every batch of MHS Longevity SLU-PP-332 is submitted to an independent third-party laboratory before release:

SLU-PP-332 as a small-molecule solid is more thermally stable than typical peptides — sealed-vial storage at refrigerated temperatures (2–8°C) is typically appropriate, with -20°C used for extended storage. Protect from light during storage; nuclear-receptor ligands often carry chromophores that are subject to photodegradation. Reconstituted working solutions in DMSO or appropriate organic-aqueous mixtures are typically held refrigerated and used within the documented stability window. Standard handling precautions for small-molecule research compounds apply.